Physiological modelling of agitation-sedation dynamics.
暂无分享,去创建一个
J G Chase | G M Shaw | J. Chase | G. Shaw | A. D. Rudge | A D Rudge | D Lee | D. Lee | Dominic S. Lee | A. Rudge | J. Chase
[1] Jörn Lötsch,et al. Pharmacokinetic modeling to predict morphine and morphine‐6‐glucuronide plasma concentrations in healthy young volunteers , 2002, Clinical pharmacology and therapeutics.
[2] Koch Sigmund Ed,et al. Psychology: A Study of A Science , 1962 .
[3] H. Schwilden,et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam , 1999, Clinical pharmacology and therapeutics.
[4] D. Crippen. The role of sedation in the ICU patient with pain and agitation. , 1990, Critical care clinics.
[5] E. Anderson. Hudson et al. , 1977 .
[6] D. Fish. Treatment of delirium in the critically ill patient. , 1991, Clinical pharmacy.
[7] J. Foss,et al. Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects? , 2004, Anesthesia and analgesia.
[8] L. Christrup,et al. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. , 2003, Journal of pain and symptom management.
[9] A. Shafer. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. , 1998, Critical care medicine.
[10] S L Shafer,et al. Response Surface Model for Anesthetic Drug Interactions , 2000, Anesthesiology.
[11] R. Waldhorn,et al. Analgesia, sedation and paralysis in the intensive care unit. , 1995, American family physician.
[12] G. Brattebø,et al. Effect of a scoring system and protocol for sedation on duration of patients' need for ventilator support in a surgical intensive care unit , 2002, BMJ : British Medical Journal.
[13] M Danhof,et al. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. , 1999, The Journal of pharmacology and experimental therapeutics.
[14] G. Guyatt,et al. Adaptation to the Intensive Care Environment (ATICE): Development and validation of a new sedation assessment instrument , 2003, Critical care medicine.
[15] A. Donner,et al. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. , 1995, Critical care clinics.
[16] W. Haefeli,et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam , 1995, The Lancet.
[17] J. Reves,et al. Sedation in the intensive care unit , 2000, Critical care medicine.
[18] A. Dahan,et al. Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy Volunteers: Absence of Sex Differences , 2004, Anesthesiology.
[19] R. Boulieu,et al. Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a bayesian pharmacokinetic software (PKS) according to sparse sampling approach , 2003, The Journal of pharmacy and pharmacology.
[20] Theodore Speroff,et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. , 2004, JAMA.
[21] J. Chase,et al. Physiologically-based minimal model of agitation-sedation dynamics , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[22] L. Smith,et al. The Pharmacokinetics of Midazolam in Chronic Renal Failure Patients , 1983, Anesthesiology.
[23] G Sherman,et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. , 1999, Critical care medicine.
[24] G C Wake,et al. Rethinking sedation and agitation management in critical illness. , 2003, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.
[25] R. Levine. Pharmacology of intravenous sedatives and opioids in critically ill patients. , 1994, Critical care clinics.
[26] G. Fraser,et al. Monitoring sedation, agitation, analgesia, and delirium in critically ill adult patients. , 2001, Critical care clinics.
[27] G. Wake,et al. Modelling and control of the agitation-sedation cycle , 2003 .
[28] J. Vender,et al. Anxiety, delirium, and pain in the intensive care unit. , 2001, Critical care clinics.
[29] A. Somogyi,et al. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. , 1996, Drug metabolism reviews.
[30] Christina Starfinger,et al. Quantifying agitation in sedated ICU patients using heart rate and blood pressure. , 2004, Physiological measurement.
[31] C. T. French,et al. Effects of a multifaceted, multidisciplinary, hospital-wide quality improvement program on weaning from mechanical ventilation , 2002, Critical care medicine.
[32] U. Hofmann,et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. , 2002, British journal of clinical pharmacology.
[33] C. Gross,et al. Sedating critically ill patients: factors affecting nurses' delivery of sedative therapy. , 2001, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[34] Dominic S. Lee,et al. Modeling and control of the agitation-sedation cycle for critical care patients. , 2004, Medical engineering & physics.
[35] W. Härdle. Applied Nonparametric Regression , 1991 .
[36] U. Klotz,et al. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction , 1998, Clinical pharmacology and therapeutics.
[37] J. Geoffrey Chase,et al. Quantifying agitation in sedated ICU patients using digital imaging , 2004, Comput. Methods Programs Biomed..
[38] J. Kress,et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. , 2000, The New England journal of medicine.
[39] D. O'Hara,et al. Pharmacokinetics and Pharmacodynamics of Sedatives and Analgesics in the Treatment of Agitated Critically Ill Patients , 1997, Clinical pharmacokinetics.
[40] Rob Janknegt,et al. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? , 1988, Clinical pharmacology and therapeutics.
[41] P. Hartvig,et al. Pharmacokinetics of midazolam in total i.v. anaesthesia. , 1987, British journal of anaesthesia.
[42] R. Moore,et al. Systematic review of factors affecting the ratios of morphine and its major metabolites , 1998, Pain.
[43] Y. Skrobik,et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool , 2001, Intensive Care Medicine.
[44] M Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of midazolam effects on the human central nervous system , 1988, Clinical pharmacology and therapeutics.